As of 6 Nov 2026, Remus Pharmaceuticals trades at ₹800.45. The shares fell 1.3% over the past year.
past year
- ₹817.00
- ₹820.00
- ₹782.00
- ₹839.80
- 7.7K
Health check
- ReturnsModest
−1.3% over the past year.
- Price tagn/a
P/E isn’t reported.
- Growthn/a
Not enough yearly results to measure.
- Profitabilityn/a
Return ratios aren’t reported.
- Balance sheetn/a
Balance sheet figures aren’t reported.
- Red flagsNone found
No warning signs in the headline numbers.
Key metrics
- Market cap
- n/a
- P/E
- n/a
- Price to book
- n/a
- Dividend yield
- n/a
- ROE
- n/a
- Return on equity
- ROCE
- n/a
- Return on capital employed
- Debt to equity
- n/a
- EPS (TTM)
- n/a
- Face value ₹10
- OPM (TTM)
- n/a
- Sales growth
- n/a
- Year-ago quarter not reported
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- n/a
Strengths and risks
Strengths and risks
Nothing stands out either way in the headline numbers.
About Remus Pharmaceuticals
No company description is available.
- ISIN
- INE0O5T01011
Price range
₹782.00₹820.00
₹782.00₹820.00
- Avg volume (3M)
- –
- 1-year return
- minus 1.3%
- From 52-week high
- minus 2.4%
Peers
We couldn’t find listed peers for this company.
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
This company doesn’t report these figures in a format we can read yet.
Forecast
Balance sheet
This company doesn’t report these figures in a format we can read yet.
Cash flow
This company doesn’t report these figures in a format we can read yet.
Shareholding pattern
71.0%
- Promoters70.95%
- Public29.05%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 70.95% | 29.05% | 0.00 | |
| 31 Mar 2026 | 70.95% | 29.05% | plus 0.04 | |
| 30 Sep 2025 | 70.91% | 29.09% | plus 0.06 | |
| 7 Jul 2025 | 70.85% | 29.15% | 0.00 | |
| 31 Mar 2025 | 70.85% | 29.15% | – |
Major shareholders
Filings & events
News
No recent news coverage found.